Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

ARTIDIS nanomekanisk genererte målinger for tidlige brystlesjoner (ANGEL)

18. september 2026 oppdatert av: ARTIDIS AG

ARTIDIS nanomekanisk genererte målinger for tidlige brystlesjoner (ANGEL)

This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

Objective: To test the performance of nanomechanical phenotype tests in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response, compared to the gold standard of histopathological assessment on testing suspicious lesions.

Study Design:

This is a multi-center, blinded, single-arm study designed to collect nanomechanical signature measurement data of biopsy material taken for clinical diagnostic purposes in subjects referred for breast biopsy. Routine demographic, diagnostic and treatment data will be collected, as well as response evaluations. Subjects with a benign biopsy will be followed for a maximum of 30 days, while subjects diagnosed with breast cancer will be kept in active, routine, clinical follow-up with information collected twice yearly for the first two years and annually for years three to ten. Intermediate treatment biopsies or tissue samples from surgery may be collected at participating sites where they are performed routinely as standard of care (SOC).

All patients referred to participating study sites for a core needle or vacuum-assisted breast biopsy may be eligible for this study. All patients will be asked for written, informed consent for de-identified tissue and data collection on disease, histology characteristics, outcome, on disease related patent information, and patient reported outcomes.

The 2nd tissue core or representative core biopsies taken from the study subjects will be further investigated with the ARTIDIS platform and subsequently re-entered into the routine pathological analysis within the same day. Only two biopsies will be assessed per ART-1 device per day. One in the morning and one in the afternoon to ensure that the diagnostic biopsy can be reentered into the routine pathological analysis. The ARTIDIS measured biopsies will be marked to identify the orientation of the biopsy in the ART-1 device before re-entering the routine pathological analysis.

For malignant and benign lesions, follow up data will be extracted from the electronic medical record, as well as standard email/phone contacts performed by the study coordinator.

In order to assess the diagnostic performance of the proposed new method, it will be compared to the current gold standard. The participants cannot be randomized by study subjects with cancer vs. non cancer study subjects and will attempt to accrue a cohort representing a range of diagnostic outcomes in order to obtain a reasonable assessment of diagnostic performance.

Participants:

Patients with suspicious lesions who are referred for biopsy following routine mammography, ultrasound, MRI, and/or clinical evaluation.

Eligible subjects will be identified from each site's pool of patients by study investigators and the research team. Subjects will be asked to participate, interviewed and follow-up by explaining the possible benefit for future patients. Patients' advocates will participate in promotion of the study, as well as development of new strategies for recruitment if necessary.

Follow-up will be done by phone and/or email after consent according to study timelines, underlining future benefits of participation for other patients.

Outcome Measures:

The outcome measures will be the performance of nanomechanical phenotype tests in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response, compared to the gold standard of histopathological assessment.

Data Analysis:

Data will be analyzed using appropriate statistical methods to compare the performance of the nanomechanical phenotype test with the gold standard histopathological assessment. The full analysis set will consist of all patients, for whom both classifications of the core biopsy material are available, the one obtained from the ARTIDIS ART-1 device and the one from classical histopathological assessment.

Conclusion:

This study aims to determine the effectiveness of the nanomechanical phenotype test in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response.

Studietype

Intervensjonell

Registrering (Antatt)

2706

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Texas
      • Dallas, Texas, Forente stater, 75390-9020
        • Rekruttering
        • University of Texas Southwestern Medical Center
        • Hovedetterforsker:
          • Basak Dogan, MD
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Baylor College of Medicine
        • Hovedetterforsker:
          • Alastair Thompson, MD
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • MD Anderson Cancer Clinic - Mays Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Therese Bevers
    • Washington
      • Seattle, Washington, Forente stater, 98195
        • Rekruttering
        • University of Washington
        • Ta kontakt med:
          • Erin Fannon, Research Manager
          • Telefonnummer: 206.685.9770
          • E-post: ecarney@uw.edu
        • Ta kontakt med:
          • Principal Investigator Meghan Flanagan, MD
    • Barcelona
      • Barcelona, Barcelona, Spania, 08035
        • Rekruttering
        • Hospital Universitario Vall d'Hebron
        • Ta kontakt med:
        • Hovedetterforsker:
          • Vicente Peg, MD.PhD
    • Basel
      • Basel, Basel, Sveits, CH-4058
        • Aktiv, ikke rekrutterende
        • Claraspital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients aged ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent.
  • Indication for breast biopsy for diagnostic purposes
  • ECOG performance status of 0 to 3.

Exclusion Criteria:

  • Conditions that, in the investigator's opinion, might indicate that the subject is not suitable for the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Human subjects requiring breast biopsy

All patients referred to participating study sites for a core needle or vacuum-assisted breast biopsy are eligible for this study. Upon consent, a diagnostic biopsy will be measured by the sponsor's device before returning to the standard of care pathway.

The ARTIDIS ART-1 device is an in-vitro diagnostic device based on Atomic Force Microscope (AFM) technology. The ART-1 device uses a probe to measure the nanomechanical phenotype of tissue components. ARTIDIS nanomechanical phenotype measurements are performed on fresh tissue after it is collected via biopsy or resection.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
ARTIDIS as a sensitive diagnostic tool
Tidsramme: Read-out on day 30

Variable, indicating a correct classification of patients' core biopsy material as malignant with the Nanomechanical Phenotype measurement in comparison to histopathological assessment as gold-standard.

Read-out on day 30
ARTIDIS as a specific diagnostic tool
Tidsramme: Read-out on day 30

Variable, indicating a correct classification of patients' biopsy material as benign with the ARTIDIS Nanomechanical Phenotype measurement in comparison to histopathological assessment as gold-standard.

Read-out on day 30

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
ARTIDIS as an aid subtyping breast cancer
Tidsramme: Read-out on day 30

Diagnostic value (sensitivity) of subtype classification of invasive breast cancer with ARTIDIS Nanomechanical Phenotype Measurement compared to classical histopathology.

Read-out on day 30
ARTIDIS imminent progression test as an indicator of local & regional progression
Tidsramme: Read-out at 6 Months and annually up to 10 years

Determine the ARTIDIS test's ability to detect local and regional progression at the time of diagnosis

Read-out at 6 Months and annually up to 10 years
ARTIDIS imminent progression test as an indicator of distant progression
Tidsramme: Read-out at 6 Months and annually up to 10 years

Determine the ARTIDIS test's ability to detect distant progression at the time of diagnosis

Read-out at 6 Months and annually up to 10 years
ARTIDIS imminent aggressiveness rating as a predictor of the pathological treatment response for patients receiving Neoadjuvant Treatment (NAT).
Tidsramme: Read out at surgery

Determine how well the ARTIDIS imminent aggressiveness rating predicts complete pathological treatment response at surgery for patients receiving Neoadjuvant Treatment.

Read out at surgery
ARTIDIS imminent aggressiveness rating as a predictor of the radiological treatment response for patients receiving Neoadjuvant Treatment (NAT).
Tidsramme: Read out at surgery

Determine how well the ARTIDIS imminent aggressiveness rating predicts radiological treatment response at the end of Neoadjuvant Treatment for patients receiving Neoadjuvant Treatment.

Read out at surgery
ARTIDIS ARTIDIS aggressiveness rating as a predictor of local recurrence-free survival time.
Tidsramme: Read-out annually up to 10 years

Determine the ability of the ARTIDIS aggressiveness rating to discriminate between patients with a high risk of recurrence and those with a low risk, adjusted for the applied cancer treatment.

Read-out annually up to 10 years
ARTIDIS ARTIDIS aggressiveness rating as a predictor of disease-free survival time.
Tidsramme: Read-out annually up to 10 years

Determine the ability of the ARTIDIS aggressiveness rating to discriminate between patients with a high risk of suffering from further disease and those with a low risk, adjusted for the applied cancer treatment.

Read-out annually up to 10 years
ARTIDIS ARTIDIS aggressiveness rating as a predictor of overall survival.
Tidsramme: Read-out annually up to 10 years

Determine the ability of the ARTIDIS aggressiveness rating to discriminate between patients with a high risk of dying from any cause and those with a low risk, adjusted for the applied cancer treatment.

Read-out annually up to 10 years
ARTIDIS potential in distinguishing benign from malignant lesions with nanomechanical profiles in relation to different tissue sources.
Tidsramme: Read-out on day 30

Variable, indicating a correct classification of patients' biopsy material by ARTIDIS Nanomechanical Phenotype Measurement in comparison to Histopathology in relation to different tissue sources (e.g. CNB, VAB, MRI guided biopsy etc.).

Read-out on day 30

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Exploratory Objective 1: ARTIDIS as an aid for diagnostic efficacy for radiologically assessed breast lesions.
Tidsramme: Read-out on day 30

Diagnostic value (sensitivity) of BI-RADS 4 assessment in combination with Nanomechanical Phenotype Measurement or without Nanomechanical Phenotype Measurement with histopathological assessment as gold-standard.

Read-out on day 30
Exploratory Objective 2: ARTIDIS as an aid for radiologist to improve the reliability of BI-RADS classification.
Tidsramme: Read-out on day 30

Diagnostic value (sensitivity) of all BI-RADS assessments in combination with Nanomechanical Phenotype Measurement or without Nanomechanical Phenotype Measurement with histopathological assessment as gold-standard.

Read-out on day 30
Exploratory Objective 3: ARTIDIS potential in improving time to treatment initiation for patients with a malignant breast lesion in comparison to standard workflow.
Tidsramme: Read-out during the follow-up visits on month 6, month 12, and then annually up to 10 years

Measurement of reduction of time to treatment initiation for patients with a high aggressive malignant lesion without ARTIDIS imminent aggressiveness measurement compared to time to treatment initiation with ARTIDIS imminent aggressiveness measurement via health care navigator interviews.

Read-out during the follow-up visits on month 6, month 12, and then annually up to 10 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Alastair Thompson, MD, Baylor College of Medicine

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. november 2023

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. november 2035

Datoer for studieregistrering

Først innsendt

28. april 2023

Først innsendt som oppfylte QC-kriteriene

10. oktober 2023

Først lagt ut (Faktiske)

17. oktober 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • ART-BrC-0102

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere